Sanofi has said the companies are prepared to roll the shot out before RSV season this fall and do not foresee any challenges meeting demand.

The first shot that protects all infants against respiratory syncytial virus, or RSV, won the unanimous backing of an advisory panel to the Centers for Disease Control and Prevention on Thursday.